Table 4.
Treatment effectiveness as observed with regard to class of previous biologic therapy.
| Timepoint (total number of patients) | Type of biologic | Number (percentage) of patients that received a certain class of previous biologic therapy | Biologic-non-naïve patients | |
|---|---|---|---|---|
| PASI (SD) | p-value | |||
| Baseline (103) | TNF-α | 20 (19.4) | 7.36 (5.52) | 0.001 |
| Il-17 | 43 (41.7) | 11.12 (8.94) | ||
| Il-12/23 | 40 (38.8) | 4.99 (4.86) | ||
| 3 months (91) | TNF-α | 17 (18.7) | 2.17 (3.29) | 0.312 |
| Il-17 | 34 (37.4) | 3.12 (5.23) | ||
| Il-12/23 | 38 (41.6) | 1.74 (2.24) | ||
| 6 months (55) | TNF-α | 10 (18.2) | 1.56 (2.32) | 0.535 |
| Il-17 | 28 (50.9) | 3.40 (5.05) | ||
| Il-12/23 | 17 (30.9) | 2.72 (4.40) | ||
| 12 months (43) | TNF-α | 5 (11.6) | 1.80 (2.00) | 0.999 |
| Il-17 | 19 (44.2) | 1.78 (2.89) | ||
| Il-12/23 | 19 (44.2) | 1.75 (2.78) | ||
Analysis of variances revealed statistically significant differences in disease severity (as measured in PASI) regarding the class of previous biologic treatment at baseline. Post hoc analysis results show significantly higher PASI in patients treated with IL-17 inhibitors as compared to those treated with IL-23 inhibitors (p < 0.001), but not TNF- α inhibitors (p = 0.147). There was no difference regarding PASI at baseline between TNF- α inhibitors and IL-12/23 inhibitors at baseline (p = 0.655).
Significant p-values are in bold.
IL, interleukin; PASI, Psoriasis Area and Severity Index; SD, standard deviation; TNF, tumour necrosis factor.